31 January 2024



Full-year and Q4 2023 results

Conference call and webcast for investors and analysts

Cautionary statement regarding forward-looking statements

This presentation may contain forward-looking statements. Forward-looking statements give the Group's current expectations or forecasts of future events. An investor can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as 'anticipate', 'estimate', 'expect', 'intend', 'will', 'project', 'plan', 'believe', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, dividend payments and financial results.

Other than in accordance with its legal or regulatory obligations (including under the Market Abuse Regulations, UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority), the Group undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Investors should, however, consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission (SEC). All investors, wherever located, should take note of these disclosures. Accordingly, no assurance can be given that any particular expectation will be met and investors are cautioned not to place undue reliance on the forward-looking statements.

Forward-looking statements are subject to assumptions, inherent risks and uncertainties, many of which relate to factors that are beyond the Group's control or precise estimate. The Group cautions investors that a number of important factors, including those in this presentation, could cause actual results to differ materially from those expressed or implied in any forward-looking statement. Such factors include, but are not limited to, those discussed under Item 3.D 'Risk factors' in the Group's Annual Report on Form 20-F for the full year (FY) 2022. Any forward-looking statements made by or on behalf of the Group speak only as of the date they are made and are based upon the knowledge and information available to the Directors on the date of this presentation.

A number of adjusted measures are used to report the performance of our business, which are non-IFRS measures. These measures are defined and reconciliations to the nearest IFRS measure are available in the Q4 2023 earnings release and Annual Report on Form 20-F for FY 2022.

All guidance, outlooks and expectations regarding future performance and the dividend should be read together with the section "Guidance and outlooks, assumptions and cautionary statements" on pages 54 to 55 of GSK's full year and Q4 2023 stock exchange announcement and "Guidance and outlooks, assumptions and basis of preparation related to 2024 guidance, 2021-26 and 2031 outlooks" in the appendix of this presentation.

Basis of preparation: On 18 July 2022, GSK plc separated its Consumer Healthcare business from the GSK Group to form Haleon, an independent listed company. Comparative figures have been restated on a consistent basis. Earnings per share, Adjusted earnings per share and Dividends per share have been adjusted to reflect the GSK Share Consolidation on 18 July 2022.



Delivering commitments and upgrading outlooks Emma Walmsley

2023 performance and guidance for 2024

Luke Miels, Deborah Waterhouse and Julie Brown

Outlooks for 2026-2031

Emma Walmsley and Julie Brown

Q&A Emma Walmsley, Tony Wood, Luke Miels, Deborah Waterhouse, Julie Brown, and David Redfern

Delivering commitments and upgrading outlooks

Emma Walmsley, Chief Executive Officer

Significant delivery and improved performance since 2021 commitments

Sales growth¹

2021: 1%

2022: 10%

2023: 14%

Launches since 2021¹

- Arexvv
- Apretude
- Cabenuva
- Jemperli
- Ojjaara


Vaccines and Specialty¹

- 2021: 58% of sales
- 2022: 62% of sales
- 2023: 66% of sales

R&D late-stage pipeline

2021 Investor Update

Progressed/acquired since 2021



- Apretude
- depemokimab
- Jemperli
- Zejula
- Blenrep
- Jesduvrog Х otilimab
- $MAPS^{2} 24v/30+v$ mRNA³ influenza TH HSV⁴ bepivirosen Brexafemme tebipenem HIV LA⁵ camlipixant Jemperli LCI⁶

CD226

Business Development⁷

Alector

Arrowhead

Halozyme

>16 Acquisitions & Alliances

Acquisitions: Hansoh Pharma Affinivax ldeya Aiolos Bio⁸ Janssen Pharma BELLUS Health Mersana Sierra Oncology Scynexis Spero Therapeutics Alliances: Springworks Vir Biotechnology

Wuxi Biologics

2023 Sales

£2.3bn

Adj. operating margin¹

- 2021: 25.6%
- 2022: 28.5%
- 2023: 28.6%

Absolute values at AER; changes at CER, unless stated otherwise

1. All values excl. COVID-19 solutions and on a continuing basis 2. Multiple Antigen Presenting System 3. Messenger RiboNucleic Acid 4. Therapeutic herpes simplex virus 5. Long acting 6. Lifecycle innovation 7. Select publicly announced acquisitions or alliances that GSK has entered into since June 2021 8. Subject to customary conditions, including applicable regulatory agency clearances under the Hart-Scott-Rodino Act in the US

Strong 2023 performance

Delivered 14%¹ sales growth, 16%¹ adj. operating profit growth

Profitable growth across portfolio:

- Vaccines 24%¹
- Specialty Medicines 15%¹
- General Medicines 5%

New products launched since 2017^2 delivered £ 11 billion sales

Trust/ESG progress sustained:

- Sector leadership recognised by S&P³
- Low-carbon *Ventolin* inhaler programme advances
- Leadership diversity ambitions achieved⁴

Highlights

Sales £30.3bn, +5% +14%¹

Adj. EPS 155.1p, +16% +22%¹ **Adj. operating profit** £8.8bn, +12%

+16%

Dividend per share

58p

Delivering on our commitments and upgrading our outlooks

2024 Guidance

- Sales growth: 5-7%
- Adj. OP growth: 7-10%
- Adj. EPS growth: 6-9%

2021-2026 New Outlook

- >7% Sales CAGR¹
- >11% Adj. operating profit CAGR¹
- >31% Adj. operating profit margin
- >£10bn CGFO²

2026-2031 New Outlook

- >£38bn sales by 2031
- Continued focus on margin improvement, with broadly stable OP⁴ margin through dolutegravir loss of exclusivity⁵

2021-2026 Previous Outlook³

- >5% Sales CAGR
- >10% Adj. operating profit CAGR
- 30% Adj. operating profit margin
- >10bn CGFO

2031 Previous Ambition³

• >£33bn sales

All guidance, outlooks and expectations regarding future performance should be read together with the section "Guidance and outlooks, assumptions and cautionary statements" on pages 54 to 55 of GSK's full-year and Q4 2023 stock-exchange announcement. 2024 guidance growth at CER, unless stated otherwise. All outlook statements are given on a CER basis and use 2023 average exchange rates as a base. All values excluding COVID-19 solutions 1. Compound annual growth rate 2. Cash flow generated from operations 3. Investor Update June 2021 4. Adj. operating profit excl. COVID-19 solutions. 5. Loss of exclusivity in the US and EU is expected in 2028-2030


2023 performance and guidance for 2024

Luke Miels, Chief Commercial Officer

Deborah Waterhouse, CEO, ViiV Healthcare and President, Global Health




Strong growth in 2023 for all product areas and regions



Absolute values at AER; changes at CER, unless stated otherwise 1. Excluding COVID-19 solutions

Vaccines: +24%¹ with outstanding Arexvy launch

Further progress expected for mRNA², MAPS³, HSV, MenABCWY and *Arexvy* in 2024



RSV (Arexvy) £1,238m⁴

 11% of 60+ population in US vaccinated against RSV; 68% vaccinated with Arexvy

Shingles (Shingrix) +17%

- 35% of >120m US adults⁵ recommended to receive Shingrix now vaccinated
- In 40 countries with <4% penetration in majority of markets
- Partnership with Zhifei⁶ in China progressing well
- Confident in delivering >£4bn in peak year sales

Meningitis +14%

- *Bexsero* +14% driven by strong growth in Europe and International
- *Menveo* +12% driven by US CDC⁷ replenishment and Brazil performance

Influenza (Fluarix/FluLaval) -29%

• Performance in line with expectations of decreased demand and commoditised market

Established vaccines +7%

2024: expect increase high-single digit to low-double digit %¹

Arexvy launch dynamics

Success in 2023, continued growth in 2024

US sets up success for global expansion


- 94.6% efficacy in comorbid population resonating well
- ~2/3 of healthcare professionals prefer Arexvy¹
- Strong position in all major pharmacies

Approved in 39 countries in 2023

- 1st entrant in US, Canada, EU and Japan
- Expect additional market approvals and reimbursements in 2024

Continued evidence generation

- 3rd year efficacy data in H1 2024
- Expand the market for at risk individuals aged 50 to 59
 - 15m people 50-59 with high-risk comorbidities for more severe RSV infections in the US²




11

GSK

1. GSK respiratory syncytial virus healthcare professional awareness trial and usage study, December 2023 2. 2023 US Census population data 3. Note: This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA – NPA for the period August 2023 – January 2024. IQVIA expressly reserves all rights, including rights of copying, distribution and republication

Specialty: +15%¹ with double-digit growth in all product areas Depemokimab and *Nucala* COPD² data in 2024



HIV +13%

• 2023 growth driven by oral two-drug regimen and long-acting portfolio

Respiratory/Immunology +18%

- Nucala +18%: strong growth in all geographies and indications driven by new patient growth and US performance. China SEA³ approval, launching in private markets; NRDL⁴ submission planned for H2 2024 based on experience with EGPA⁵
- Benlysta +19%: growth in major markets and continued market expansion; updated KDIGO⁶ guidelines in LN⁷ now recommend use at initial therapy driving further penetration with only ~25% use in the class

Oncology +23%


- Ojjaara £33m⁸: strong launch building momentum, first and only treatment indicated for myelofibrosis patients with anaemia in US
- *Jemperli* £141m⁸: continued momentum and growth in 1L⁹ endometrial cancer in the US; EU 1L endometrial cancer approval in Dec 2023¹⁰
- *Zejula* +15%: driven by US tablet introduction, global expansion and new patient starts
- *Blenrep* -69%: positive phase III interim analysis of DREAMM-7 head-tohead with daratumumab, DREAMM-8 phase III data expected H2 2024

2024: expect increase low-double digit %¹

Absolute values at AER; changes at CER for full year, unless stated otherwise


1. Excluding COVID-19 solutions 2. Chronic obstructive pulmonary disease 3. Severe eosinophilic asthma 4. national reimbursement drug list 5. Eosinophilic granulomatosis with polyangiitis 6. Kidney Disease Improving Global Outcomes 7. Lupus nephritis 8. FY 2023 global sales 9. First line 10. 11 December 2023: *Jemperli* plus chemo approved as first and only frontline IO treatment in EU for dMMR/MSI-H primary advanced or recurrent endometrial cancer

General Medicines: +5% driven by *Trelegy* in respiratory



Respiratory +6%

 Trelegy +29%: Top-selling brand in asthma and COPD¹ market worldwide; delivering >£2bn in 2023



- Benefit of *Arexvy* co-promotion and prevention/treatment approach leading to longer sales calls
- SITT³ Class displacing ICS⁴/LABA⁵ with GOLD⁶ guidelines and early optimisation message accelerating growth

Other General Medicines +2%

- Augmentin +17%
- Emerging Markets +15%
- Up to \$700m sales exposure related to US AMP⁷ Cap removal; Q4 2023 accrued \$150m related to rebates and inventory burn

2024: expect decrease mid-single digit %

Absolute values at AER; changes at CER for full year, unless stated otherwise


IQVIA MIDAS® monthly data, since launch up to (and including) August 2023, reflecting estimates of real-world activity

 1. Chronic obstructive pulmonary disease
 2. GSK Annual Reports 2020-23; FactSet major competitor sales in GBP
 3. Single inhaler triple therapy
 4. Inhaled corticosteroid
 5. Long-acting beta-agonists

 6. Global Initiative for Chronic Obstructive Lung Disease
 7. Average Manufacturer Price

HIV: 13% growth in 2023 driven by oral two-drug regimen (2DR) and long-acting (LA) portfolio

Strong execution across portfolio



Growth driven by oral 2DR and LA injectables

- FY 2023 sales of £6.4bn driven by oral 2DR and LA injectable regimens
- Oral 2DR and LA regimens >50% of total HIV portfolio
- Dovato sales of £1.8bn leading oral 2DR
- Cabenuva sales of £708m growing >100% vs 2022
- Apretude sales of £149m potential to transform PrEP¹
- Pipeline: Data to be presented at CROI² in March Target dosing intervals for LA regimens extended to every four months in treatment and prevention with roadmap to reach every six months by end of decade

2023 performance and guidance for 2024

Julie Brown, Chief Financial Officer

Delivered a step-change in financial performance in 2023

	2022	2023	AER	CER	Key commentary on CER basis
Adjusted results	£m	£m	%	%	
Sales	29,324	30,328	3	5	Sales grew +14% (excl. COVID-19 solutions) with strong growth in Vaccines (<i>Arexvy</i> and <i>Shingrix</i>) and HIV
Cost of sales	(8,741)	(7,716)	(12)	(11)	Benefit from lower sales of lower margin Xevudy and favourable mix
Gross profit	20,583	22,612	10	12	
Gross profit margin	70.2%	74.6%	+440 bps	+460 bps	Improved +20 bps (excl. COVID-19 solutions)
SG&A	(8,128)	(9,029)	11	13	Increased investment for growth in Vaccines and HIV
Research and development	(5,062)	(5,750)	14	14	Increased investment in late-stage Vaccines and new product launches
Royalties	758	953	26	26	Benefit from Gardasil, Kesimpta and Biktarvy
Operating profit	8,151	8,786	8	12	Grew +16% (excl. COVID-19 solutions)
Operating profit margin	27.8%	29.0%	+120 bps	+180 bps	Improved + 60 bps (excl. COVID-19 solutions)
Earnings per share	139.7p	155.1	11	16	EPS grew +22% (excl. COVID-19 solutions)
	2022	2023	AER	CER	
<u>Total results</u>	£m	£m	%	%	
Total operating profit	6,433	6,745	5	10	
Total operating profit margin	21.9%	22.2%	+30 bps	+100bps	
Total earnings per share	110.8p	121.6p	10	16	



Adjusted results for continuing operations unless stated otherwise; some figures may not sum due to rounding. See page 20 of GSK's full-year and Q4 2023 stock-exchange announcement for a full reconciliation of Total to Adjusted results


Improved 2023 adjusted operating margin

Excluding COVID-19 solutions +60 bps CER

Margin benefits driven by improved productivity and increased royalties

Including COVID-19 solutions +180 bps CER

Margin benefit driven by decline in lower margin *Xevudy* and increased royalties



2023 free cash flow of £3.4bn

Cash generated from operations of £8.1bn

	£m	£m
	2022	2023
Adj. operating profit	8,151	8,786
Decrease/(Increase) in working capital	67	(1,233)
Gilead Science, Inc. settlement income	927	-
Other CGFO ¹	(1,201)	543
Cash generated from operations	7,944	8,096
Taxation paid	(1,310)	(1,328)
Net capex ²	(1,916)	(2,304)
Other ³	(1,370)	(1,055)
Free cash flow	3,348	3,409
Net debt	17,197	15,040

Key drivers of cash flow

Full year

Cash generated from operations increased despite annualising the Gilead Science, inc settlement in 2022 (£0.9bn) due to:

- Higher Adjusted Operating profit
- Favourable timing of *Xevudy* cashflows
- Lower UK special pension contributions
- Partly offset by higher receivables from *Arexvy* sales


Net capital investment increased primarily due to lower proceeds from asset disposals than in 2022

Q4 2023

Extremely strong quarter, delivering £3.7bn cash from operations versus £2.1bn in 2022, including benefit from *Arexvy* collections from Q3 launch

1. Cash generated from operations, including changes in returns and rebates, significant legal payments and operating contingent consideration liability payments 2. Net Capex includes purchases less disposals of property, plant and equipment and intangibles 3. Other includes net interest paid and dividends to Non-Controlling Interests

Capital deployment supports business growth and shareholder returns





1. Free Cash Flow (FCF) is £3.4bn, including the capital expenditure net of disposal proceeds for plant, property & equipment and intangibles of £1.3bn and £1.0bn, respectively (included in targeted business development above) 2. Targeted BD in the above chart includes net intangible capex, net purchase of businesses, and net equity investment 3. Other includes dividend and distribution income, exchange on net debt and other financing items

2024 guidance at CER (excl. COVID-19 solutions)

Guidance

- Sales: 5% to 7% growth
- Adj. operating profit: 7% to 10% growth
- Adj. earnings per share: 6% to 9% growth

2024 modelling considerations

Sales

- Vaccines: high single- to low double-digit % increase
- Specialty Medicines¹: low double-digit % increase
 - HIV: high single- to low double-digit % increase
- General Medicines: mid-single digit % decrease

P&L

- SG&A: low single-digit increase
- **R&D**: increase broadly in line with sales to support growth of pipeline
- Royalties: £500-£550m; minimal Gardasil royalties (2023: £472m)
- Net finance expense: slightly lower than 2023
- Adjusted Tax rate: around 17%

Outlooks for 2026-2031

Emma Walmsley, Chief Executive Officer Julie Brown, Chief Financial Officer

Delivering profitable growth 2026-2031

Build from existing strong performance momentum

Marketed Growth Drivers ≥£2bn PY	rS1	Innova
Arexvy Cabenuva/Apreto Shingrix Nucala Meningococcal Benlysta vaccines ² Oncology ³ Sales >7% CAGR ⁴	ude	 Significant increasing Specialty m
Planned launches ≥£2	2bn⁵ PYS¹	• >12 major p
Meningococcal vaccines ² mRNA influenza HIV PrEP ⁶ depemokimab camlipixant Anti-infectives ⁷	MAPS 24v/30v+ Jemperli LCI ⁸ TH HSV CD226 bepirovirsen HIV treatment ⁶ Sales >£38bn RA ⁹	2025 >£3
	Early-stage pipeline with key inflections and launches	
	Phase II: 30 vaccines and medicines in development ¹⁰ Phase I: 23 vaccines and medicines in development ¹⁰	 With upsid Early-stage readouts
	+ targeted business development	 Targeted b
2026	2031	

ation-led growth

- t growth portfolio with sales from Vaccines and medicines
- product launches from

38 billion RA⁹


de opportunity from:

- e pipeline data
- business development



All outlook statements are given on a constant currency basis and use 2023 average exchange rates as a base. Pipeline sales are risk-adjusted and include anticipated sales of new products and lifecycle innovation. COVID therapeutic and vaccines solutions sales and profits (2021-2023) are excluded from the above. See "Guidance and outlooks, assumptions and basis of preparation related to 2024 guidance, 2021-26 and 2031 outlooks" in Appendix of this presentation. 1. Peak year sales 2. Meningococcal vaccines (Bexsero and MenABCWY) 3. Includes Zejula, Jemperli, and Ojjaara 4. Compound annual growth rate 5. Does not include Blenrep 6. Every-four-month ultra long-acting dosing, >£2bn applies to the aggregation of sales of PrEP and treatment. 7. Includes gepotidacin, tebipenem HBr and Brexafemme 8. Lifecycle nnovation 9. Risk-adjusted sales 10. See the appendix for a full list of vaccines and medicines in clinical development

2031 sales outlook: high potential and attractive risk profile



Pipeline opportunity 2031 sales outlook of \geq £38bn provided on risk adjusted basis More than 90% of sales supporting 2031 • outlook of >£38 bn come from products already approved, or from planned launches \geq £2bn, with majority planned for launch in next four years Significant potential upside with successful development outcomes and targeted BD

2031 risk adjusted sales

2031 non risk adjusted sales

GSK

Charts are schematic and not to scale. All outlook and ambition statements are given on a constant currency basis and use 2023 average exchange rates as a base. Pipeline sales are risk-adjusted and include anticipated sales of new vaccines and medicines and life cycle innovation. See "Guidance and outlooks, assumptions and basis of preparation related to 2024 guidance, 2021-26 and 2031 outlooks" in appendix. 1. Does not include *Blenrep*

Significant future pipeline value "unlocks" in 2024-2026


Scale opportunities in all core product areas

Launch year and NRA PYS¹ potential of major launches 2026-31

Vac	cines	Specialty	Specialty Medicines		
2025+ MenABCWY/ <i>Bexsero</i> – Meningococcal vaccines ~£2bn in peak year sales ¹	2027+ MAPs - pneumococcal disease 24/30+ >£4bn in peak year sales ¹	2026+ HIV Q4M ULA prevention and treatment >£3bn in peak year sales ¹	2026 camlipixant - refractory chronic cough >£2.5bn in peak year sales ¹	2025+ Anti-infectives ² ~£2bn in peak year sales ¹	
2026+ mRNA seasonal flu and combinations – Influenza >£3bn in peak year sales ¹	2028 TH HSV ³ – suppress recurrence of genital herpes >£2bn in peak year sales ¹	2027 bepirovirsen - hepatitis B virus >£2bn in peak year sales ¹ 2025+ depemokimab / IL5 – <i>Nucala</i> COPD >£4bn	2027+ <i>Jemperli</i> LCI - lung, colorectal and head & neck >£2bn in peak year sales ¹ 2031 CD226 – exploratory oncology indications >£2bn		
		in peak year sales ¹	in peak year sales ¹		

All outlook statements are given on a constant currency basis and use 2023 average exchange rates as a base. See "Guidance and outlooks, assumptions and basis of preparation related to 2024 guidance, 2021-26 and 2031 outlooks" in appendix. 1. Non-risk adjusted peak year sales potential 2. Anti-infectives includes gepotidacin, tebipenem HBr and *Brexafemme* 3. Therapeutic herpes simplex virus

Sustained focus on operating margin improvement



Key drivers

- Sales mix shift to Vaccines and Specialty Medicines
- Productivity across supply chain, commercial and functions
- Major restructuring complete

Headwinds

• Gardasil royalties end in 2023

2026 - 2031

Continued focus on margin improvement, with broadly stable OP margin through dolutegravir loss of exclusivity (2028-2030)¹

Key drivers

- HIV portfolio transition (~40% of HIV business in long-acting therapies anticipated at start of loss of exclusivity in US/EU)
- Operating margin mix benefit from Vaccine and Specialty Medicines marketed and new pipeline products
- >12 major product launches planned 2026-31
- Expected productivity gains in supply chain and SG&A, with increased use of AI and analytics

Headwinds

• Dolutegravir LOE (from 2028-2030 (US/EU) with majority impact 2029-2030

Upside opportunity through additional revenue growth

• Early-stage pipeline progression and targeted BD

All outlook statements are given on a constant currency basis and use 2023 average exchange rates as a base. See "Guidance and outlooks, assumptions and basis of preparation related to 2024 guidance, 2021-26 and 2031 outlooks" in appendix. Operating margin bridge excludes COVID-19 solutions; FX: 2021 reported margin at 2021 average exchange rates. 2023 and 2026 at 2023 average exchange rates. Basis point movement at CER. 1. Anticipated loss of exclusivity from 2028-2030 in US/EU

Capital allocation framework to support investment and returns

Priority is to invest for growth, coupled with attractive shareholder returns



2

Invest for growth

Pipeline (organic and targeted BD) New product launches Shareholder distributions

Progressive dividend (40-60% pay-out ratio) Excess cash returns

Underpinned by strong balance sheet with strong investment grade credit rating

Attractive and growing shareholder returns

2022¹ dividend

55p/share

2023 dividend expect 58p/share 2024 dividend expect 60p/share



	o 2024 to 2025 H1 2024		H2 2024*	2025
Execution	 Full year 2023 results Guidance 2024 Q1 2024 results 		 Half-year 2024 results Q3 2024 results 	 Full-year 2024 results Guidance 2025 Q1 2025 results Half-year 2025 results Q3 2025 results
Pipeline Phase III and regulatory decisions ²	 Ojjaara/Omjjara: MOMENTUM, myelofibrosis (JP) Ojjaara/Omjjara: MOMENTUM, myelofibrosis (EU) Nucala: severe asthma (CN) 	5 5	 Arexvy, RSV, 50-59 YoA (US, EU, JP) Nucala, nasal polyposis (JP) 	 gepotidacin: EAGLE MenABCWY 1st gen (US, EU)⁴ Jemperli RUBY (Part 1) EC³ 1L (US) Blenrep, DREAMM-7/82 L+ MM^{1,8} (US, EU, CN, JP) depemokimab ANCHOR-1/2 CRSwNP⁹, (US) depemokimab SWIFT-1/2 SEA¹⁶ (US) gepotidacin uUT1¹⁰, GC¹¹ (US) Nucala MATINEE COPD¹² (EU, CN) Nucala CRSwNP⁹ (CN) Zejula ZEAL, 1L maintenance NSCLC (US) linerixibat cholestatic pruritus (US, EU, CN, JP)
	 gepotidacin EAGLE-1, GC¹¹ depemokimab SWIFT-1/2, SEA¹⁶ Zejula FIRST 1L maintenance OC Jemperli RUBY, 1L dMMR/MSI-H EC³ (EU) Jemperli RUBY Part 1L OS⁵ EC³ Jemperli RUBY Part 2, 1L EC³ Blenrep DREAMM-7, 2L+MM^{1.8} 		 depemokimab ANCHOR-1/2, CRSwNP Nucala MATINEE, COPD Blenrep DREAMM-8, 2L+ multiple myeloma¹ cobolimab COSTAR, 2L NSCLC⁶ Zejula ZEAL, 1L maintenance NSCLC⁶ linerixibat GLISTEN, PBC⁷ 	 depemokimab OCEAN, EGPA ¹³ camlipixant CALM 1/2, RCC¹⁴ tebipenem PIVOT-PO, cUTI¹⁵
Capital Allocation	Full-year 2023 dividend declarationDividend expectation 2024			Full-year 2024 dividend declarationDividend expectation 2025
Investor engagement	Meet the management, Oncology		 Meet the management, Early pipeline Roadshows and Medical congresses 	

GSK

* HIV long-acting combination decision 1. Not included in the updated outlook 2. Includes phase III data readouts and regulatory decisions with the applicable geography denoted in brackets 3. Endometrial cancer 4. Regulatory submission and acceptance 5. Overall survival overall population Phase III data readout; 6. Non-Small Cell Lung Cancer 7. Cholestatic pruritus in primary biliary cholangitis 8 Multiple Myeloma; 9 Chronic rhinosinusitis with nasal polyps 10 Uncomplicated Urinary Tract Infections 11. Urogenital gonorrhoea 12 Chronic Obstructive Pulmonary Disease 13 Eosinophilic granulomatosis with polyangiitis 14. Refractory Chronic Cough 15. Complicated urinary tract infection 16. Severe eosinophilic asthma

Focused on prevention and changing the course of disease

CD S H Ahead Together

R&D based on science of the immune system and use of new platform and data technologies

Leaders in development of new Vaccines and Specialty Medicines, for Infectious Diseases, HIV Respiratory/Immunology and Oncology Products that improve the health of millions of people, and sector leaders in ESG performance

Strong momentum and improving outlook for sustained growth through the decade





2024 full year outlook considerations to support modelling

	2023 growth excl Covid	2024 Guidance	2024 Assumptions	2021 – 2026 BIU 2021	2021 – 2026 BIU 2024
Turnover	+14%	5-7%		>5% CAGR	>7% CAGR
- Vaccines	+24%	HSD – LDD		HSD CAGR	LDD CAGR
- Specialty	+15%	LDD		DD CAGR	DD CAGR
- HIV	+13%	HSD – LDD		MSD CAGR	6-8% ¹
- Gen Meds	+5%	MSD decr	Largely Amp Cap removal	Broadly Stable	Broadly Stable
Adj. Operating Profit	+16%	7-10%	SG&A: LSD increase R&D: increase broadly in line with sales Royalties: £500-£550m; minimal Gardasil royalties	≻10% CAGR	>11% CAGR
Adj. Op. Profit margin	28.6%	n/a		>30%	>31%
Adj EPS	+ 22%	6-9%	Interest: slightly lower than 2023 Tax rate: around 17% Non-controlling interest: ViiV is main ongoing NCI		1
Dividend	58p	60p			



All guidance, outlooks and expectations regarding future performance should be read together with the section "Guidance and outlooks, assumptions and cautionary statements" on pages 54 to 55 of of GSK's fullyear and Q4 2023 stock-exchange announcement. 2024 guidance growth at CER, unless stated otherwise. All outlook statements are given on a CER basis and use 2023 average exchange rates as a base. All values excluding COVID-19 solutions. CAGR is compound annual growth rate. 1. As per HIV Meet The Management event, 28 September 2023

2023 Total to adjusted operating profit reconciliation

	2022	2023	Key commentary on CER basis
	Operating profit (£m)	Operating profit (£m)	
Total results	6,431	6,745	+10% at CER
Intangible amortisation	739	719	
Intangible impairment	296	398	
Major restructuring	321	382	~£1.1bn benefits to date ¹
Transaction-related	1,750	572	ViiV CCL ² movements
Divestments, significant legal and other	(1,388)	(30)	Receipt of dividend and distribution income from investments, legal fees and settlements
Adjusted results	8,151	8,786	+ 12% at CER

Improved adj. earnings per share with +16% growth at CER

	2022 £m	2023 £m	Key commentary on CER basis
Adj. operating profit (OP)	8,151	8,786	+12% incl. COVID; +16% excl. COVID-19 solutions
Net finance expense	(791)	(669)	Lower bond interest costs and higher interest income
Share of associates	(2)	(5)	
Тах	(1,138)	(1,257)	
Tax rate	15.5%	15.5%	In-line with guidance
Non-controlling interests	(595)	(572)	Lower net profits in some Group entities
Adj. Profit attributable to shareholders	5,625	6,283	+17% incl. COVID
Adj. earnings per share (EPS)	139.7p	155.1p	+16% incl. COVID, +22% excl. COVID-19 solutions
Total EPS	110.8p	121.6p	+16% at CER
Weighted average number of shares (millions)	4,026	4,052	

• Quarterly summary of results

	2022					2023					
	Ql	Q2	Q3	Q4	FY	Ql	Q2	Q3	Q4	FY	
Including COVID-19 solutions											
Sales (£m)	7,190	6,929	7,829	7,376	29,324	6,951	7,178	8,147	8,052	30,328	
Operating profit (£m)	1,943	2,008	2,605	1,595	8,151	2,092	2,170	2,772	1,752	8,786	
Operating margin	27.0%	29.0%	33.3%	21.6%	27.8%	30.1%	30.2%	34.0%	21.8%	29.0%	
Earnings per share (pence) post-share consolidation	32.3	34.7	46.9	25.8	139.7	37.0	38.8	50.4	28.9	155.1	
COVID-19 solutions impact											
Sales (£m)	1,307	466	417	183	2,373	132	41	1	20	194	
Operating profit (£m)	194	58	141	69	462	118	57	(4)	9	179	
Earnings per share (pence) post-share consolidation	4.1	1.2	2.9	1.5	9.7	2.5	1.2	(0.1)	0.2	3.8	
Excluding COVID-19 solutions impact											
Sales (£m)	5,883	6,463	7,412	7,193	26,951	6,819	7,137	8,146	8,032	30,134	
Operating profit (£m)	1,749	1,950	2,464	1,526	7,689	1,974	2,113	2,776	1,743	8,607	
Operating margin	29.7%	30.2%	33.2%	21.2%	28.5%	28.9%	29.6%	34.1%	21.7%	28.6%	
Earnings per share (pence) post-share consolidation	28.2	33.5	44.0	24.3	130.0	34.5	37.6	50.5	28.7	151.3	



2023 currency sales exposure¹

US \$	52%	US \$: 10 cents movement in the average exchange rate for full year impacts adj. operating profit by approx. +/- 9.0%
Euro €	19%	Euro €: 10 cents movement in the average exchange rate for full year impacts adj. operating profit by approx. +/- 0.5%
Japanese ¥	4%	Japanese ¥: 10 Yen movement in the average exchange rate for full year impacts adj. operating profit by approx. +/- 1.0%
Other ²	25%	

	2022					2023					
Historical average exchange rates quarterly	QÌ	Q2	Q3	Q4	FY 22	Q1	Q2	Q3	Q4	FY 23	
US \$	1.34	1.26	1.18	1.19	1.24	1.22	1.25	1.26	1.25	1.24	
Euro €	1.19	1.18	1.16	1.15	1.17	1.14	1.15	1.16	1.15	1.15	
Japanese ¥	156	162	161	165	161	162	173	182	183	175	
Historical period end exchange rates											
US \$	1.31	1.21	1.11	1.20		1.24	1.26	1.23	1.27		
Euro €	1.18	1.16	1.13	1.13		1.14	1.17	1.16	1.15		
Japanese ¥	160	165	160	159		165	183	183	180		

GSK

1. Based on 2023 GSK continuing operations, including COVID-19 solutions 2. The other currencies that each represent more than 1% of GSK sales include Australian Dollar, Brazilian Real, Canadian Dollar, Chinese Yuan and Indian Rupee. In total, they accounted for 9% of GSK revenues in 2023. 3. If exchange rates were to hold at the closing rates on 24 January 2024 (\$1.27/£1, €1.17/£1 and Yen 188/£1) for the rest of 2024, the estimated impact on 2024 Sterling turnover growth for GSK would be -3% and if exchange gains or losses were recognised at the same level as in 2023, the estimated impact on 2024 Sterling Adjusted Operating Profit growth for GSK would be -5%.

2024 adj. operating profit³

Investor roadmap highlights progress of key events

	Q2 2023	Q3 2023	Q4 2023		H1 2024		H2 2024
Execution	 Q2 and Half-year 2023 results Full-year 2023 upgraded guidance 		 Full-year and Q4 20 results Performance vs BIU 2021¹ Full-year 2024 guide 	\checkmark	 Q1 2024 results Q2 and Half-year 2024 results 	_	 Q3 and Year-to-date 2024 results Full-year and Q4 2024 results Performance vs BIU 2021¹ Guidance 2025
Pipeline Phase III and regulatory decisions ²	 Therapy Area Strategy R&D priorities Arexvy US regulatory approval Arexvy second season data BELLUS Health, Inc. acquisition completed SCYNEXIS, Inc. exclusive license completed 	 Apretude, HIV pre-expose Vocabria, HIV treatment (Ojjaara, MOMENTUM, m Jemperli RUBY, 1L dMMR 	ure (EU) (CN) yelofibrosis (US)		 Jemperli: RUBY, 1L dMMR/MSI-H EC³ (EU) Ojjaara: MOMENTUM, myelofibrosis (EU) Ojjaara: MOMENTUM, myelofibrosis (JP) Blenrep: DREAMM-7, 2L+ MM gepotidacin: EAGLE-1, GC depemokimab: SWIFT-1/2, asthma Jemperli: RUBY (Part 2), 1L EC³ Jemperli: RUBY (Part 1) 1L OS⁴ EC³ Zejula: FIRST, 1L maintenance OC ovarian cancer 		 Arexvy: RSV, 50-59 YoA (US, EU, JP) Nucala: CRSwNP (JP) Nucala: severe asthma (CN) depemokimab: ANCHOR-1/2, CRSwNP Nucala MATINEE, COPD cobolimab: COSTAR, 2L NSCLC Blenrep: DREAMM-8, 2L MM Zejula: ZEAL, 1L maintenance NSCLC linerixibat: GLISTEN, PBC⁵
Capital Allocation	 Capital allocation R&D and BD priorities TA priorities 	2	• Full-year 2023 dividend declaration				• Full-year 2024 dividend declaration
Investor Engagement	 Meet the management, Infectious Diseases 	Meet the management, HIV	Meet the management, Respiratory	Roadsho V	ows Meet the management, Oncology		
	•		——— M	edical con	ngresses		→

GSK

Upcoming pipeline catalysts: 2024 and 2025


Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven

	H1 2024		H2 2024		2025	
Regulatory	Ojjaara/Omjjara: MOMENTUM, myelofibrosis	JP	Arexvy: 50-59 YoA ¹⁰	US, EU, JP	gepotidacin: EAGLE-2/3, uUTI ¹¹	US
decision	—		Nucala: CRSwNP ¹	JP	gepotidacin: EAGLE-1, GC⁵	US
					MenABCWY vaccine 1st Gen	US, EU
					depemokimab: SWIFT-1/2, asthma	US
					depemokimab: ANCHOR-1/2, CRSwNP ¹	US
					Nucala: CRSwNP ¹	CN
					Nucala: MATINEE, COPD ¹²	US
					Blenrep: DREAMM-7/8, 2L+ MM ⁷	US, EU, CN, JP
					Jemperli ² : RUBY (Part 1) ^{3.} 1L EC ⁴	US
					linerixibat: GLISTEN, cholestatic pruritus in PBC ¹⁴	US
Regulatory	MenABCWY vaccine 1st Gen	US	gepotidacin: EAGLE-2/3, uUTI ¹¹	US	gepotidacin: EAGLE-1, GC⁵	US
submission and	Nucala: CRSwNP ¹	CN	MenABCWY vaccine 1st Gen	EU	tebipenem pivoxil: PIVOT-PO, cUTI ¹⁵	US
acceptance	Jemperli ² : RUBY (Part 1) ³ , 1L EC ⁴	US	depemokimab: SWIFT-1/2, asthma	US	camlipixant: CALM-1/2, RCC ¹⁶	US, EU
	—		depemokimab: ANCHOR-1/2, CRSwNP ¹	US	Nucala: MATINEE, COPD ¹²	EU, CN
			Nucala: MATINEE, COPD ¹²	US	Blenrep: DREAMM-7/8, 2L+ MM ⁷	US, EU, CN, JP
			—		cobolimab ² : COSTAR, 2L NSCLC ¹³	US, EU
					linerixibat: GLISTEN, cholestatic pruritus in PBC ¹⁴	US, EU, CN, JP
Late-stage phase	gepotidacin: EAGLE-1, GC⁵		depemokimab: ANCHOR-1/2, CRSwNP ¹		tebipenem pivoxil: PIVOT-PO, cUTI ¹⁵	
III and phase II	depemokimab: SWIFT-1/2, asthma		Nucala: MATINEE, COPD ¹²		camlipixant: CALM-1/2, RCC ¹⁶	
readouts	Blenrep: DREAMM-7 ⁶ , 2L+ MM ⁷		Blenrep: DREAMM-8, 2L+ MM ⁷		depemokimab: OCEAN, EGPA ¹⁷	
	Zejula ² : FIRST, 1L maintenance OC ⁸		cobolimab ² : COSTAR, 2L NSCLC ¹³		—	
	—		Zejula ² : ZEAL, 1L maintenance NSCLC ¹³			
	mRNA Seasonal flu ⁹		linerixibat: GLISTEN, cholestatic pruritus in PBC	214		

GSK

1. Chronic rhinosinusitis with nasal polyps 2. Tesaro asset 3. Overall population 4. Endometrial cancer 5. Uragenital gonorrhoea 6. Overall survival 7. Multiple myeloma 8. Ovarian cancer 9. Phase II 10. Years of age 11. Uncomplicated urinary tract infection 12. Chronic obstructive pulmonary disorder 13. Non-small cell lung cancer 14. Treatment of cholestatic pruritus in primary biliary cholangitis 15. Complicated urinary tract infection 16. Refractory chronic cough 17. Eosinophilic granulomatosis with polyangiitis

12 major planned launches



MenABCWY mRNA influenza Anti-infectives (gepotidacin, tebipenem and Brexafemme) MAPs 24v/30+v TH HSV (herpes simplex virus) bepirovirsen HIV PrEP HIV treatment depemokimab camlipixant Jemperli LCI CD226

Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven

71 potential new vaccines and medicines in pipeline

Phase III / Registration – 18 assets

Arexvy (RSV vaccine)	Recombinant protein, adjuvanted*	RSV older adults (50-59 YoA)^
gepotidacin (2140944)	BTI inhibitor*	Uncomplicated UTI**
bepirovirsen (3228836)	Antisense oligonucleotide*	Chronic HBV infection**
Bexsero (MenB vaccine)	Recombinant protein, OMV	Meningitis B (infants US)
MenABCWY vaccine (3536819)	Recombinant protein, OMV, conjugated vaccine	MenABCWY, 1 st Gen
tebipenem pivoxil (3778712)	Antibacterial carbapenem*	Complicated UTI
ibrexafungerp (5458448)	Antifungal glucan synthase inhibitor*	Invasive candidiasis
<i>Nucala</i> (mepolizumab)	Anti-IL5 antibody	COPD
depemokimab (3511294)	Long-acting anti-IL5 antibody*	Asthma**
latozinemab (4527223)	Anti-sortilin antibody*	Frontotemporal dementia ¹ **
camlipixant (5464714)	P2X3 receptor antagonist	Refractory chronic cough
Low carbon version of MDI ² , <i>Ventolin</i> (salbutamol)	Beta 2 adrenergic receptor agonist	Asthma ³
<i>Ojjaara/Omjjara</i> (momelotinib)	JAK1, JAK2 and ACVR1 inhibitor*	Myelofibrosis^4
<i>Jemperli</i> (dostarlimab)	Anti-PD-1 antibody*	Endometrial cancer^**
<i>Zejula</i> (niraparib)	PARP inhibitor*	Ovarian cancer**
Blenrep (belantamab mafodotin)	Anti-BCMA ADC*	Multiple myeloma
cobolimab (4069889)	Anti-TIM-3 antibody*	Non-small cell lung cancer
linerixibat (2330672)	IBAT inhibitor	Cholestatic pruritus in primary biliary cholangitis



- 71 potential new vaccines and medicines in pipeline

Phase II – 30 assets

3437949	Recombinant protein, adjuvanted*	Malaria fractional dose
4406371	Live, attenuated	MMRV new strain
3536852	GMMA*	Shigella
3528869	Viral vector with recombinant protein, adjuvanted*	Chronic HBV infection ⁵ **
4023393	Recombinant protein, OMV, conjugated vaccine	MenABCWY, 2 nd Gen ⁵
4178116	Live, attenuated	Varicella new strain
5101956	MAPS*	Adult pneumococcal disease, 24-valent
5101955	MAPS*	Paediatric pneumococcal disease, 24-valent
4106647	Recombinant protein, adjuvanted*	Human papillomavirus ⁵
4348413	GMMA	Gonorrhoea ⁵
4382276	mRNA*	Seasonal flu
4396687	mRNA*	COVID-19
3993129	Adjuvanted recombinant subunit	Cytomegalovirus ⁵
3943104	Recombinant protein, adjuvanted*	Therapeutic herpes simplex virus ⁵
5637608	Hepatitis B virus-targeted siRNA*	Chronic HBV infection
4077164	Bivalent GMMA	Invasive non-typhoidal salmonella**
3036656	Leucyl t-RNA synthetase inhibitor*	Tuberculosis
sanfetrinem cilexetil (GV118819)	Serine beta lactamase inhibitor*	Tuberculosis
BVL-GSK098	Ethionamide booster*	Tuberculosis
3810109	Broadly neutralizing antibody*	HIV
3739937	Maturation inhibitor	HIV
4004280	Capsid protein inhibitor	HIV
4011499	Capsid protein inhibitor	HIV
4524184	Integrase inhibitor*	HIV ⁶
Benlysta (belimumab)	Anti-BLys antibody	Systemic sclerosis associated interstitial lung disease
3858279	Anti-CCL17 antibody*	Osteoarthritis pain**
1070806	Anti-IL18 antibody	Atopic dermatitis
4527226 (AL-101)	Anti-sortilin antibody*	Alzheimer's disease ⁶
belrestotug (4428859)	Anti-TIGIT antibody*	Non-small cell lung cancer**
4532990	HSD17B13 siRNA*	Non-alcoholic steatohepatitis

GSK ^{*In-}

*In-license or other alliance relationship with third party ** Additional indications or candidates also under investigation ^ In registration

1. Phase III trial in patients with progranulin gene mutation 2. Metered dose inhaler 3. Phase III start expected in 2024 4. Approved in US and EU 5. In phase I/II study 6. Phase II study start imminent 7. Transition activities underway to enable further progression by partner 8. GSK has an exclusive global license option to co-develop and commercialise the candidate

Infectious diseases HIV (ViiV) Respiratory/Immunology Oncology Opportunity driven

- 71 potential new vaccines and medicines in pipeline

Phase I – 23 assets

3536867	Bivalent conjugate*	Salmonella (typhoid + paratyphoid A)
2556286	Mtb cholesterol dependent inhibitor*	Tuberculosis
3186899	CRK-12 inhibitor* ⁷	Visceral leishmaniasis
3494245	Proteasome inhibitor*	Visceral leishmaniasis
3772701	P. falciparum whole cell inhibitor*	Malaria
4024484	P. falciparum whole cell inhibitor*	Malaria
3882347	FimH antagonist*	Uncomplicated UTI
3923868	PI4K beta inhibitor	Viral COPD exacerbations
3965193	PAPD5/PAPD7 inhibitor	Chronic HBV infection ⁵
5251738	TLR8 agonist*	Chronic HBV infection
cabotegravir (1265744)	Integrase inhibitor	HIV
3888130	Anti-IL7 antibody*	Autoimmune disease
3915393	TG2 inhibitor*	Pulmonary fibrosis
3862995	Anti-IL33 antibody	COPD
5462688	RNA-editing oligonucleotide*	Alpha-1 antitrypsin deficiency
4347859	Interferon pathway modulator	Systemic lupus erythematosus
4381562	Anti-PVRIG antibody*	Cancer
6097608	Anti-CD96 antibody*	Cancer
XMT-2056 ⁹ (wholly owned by Mersana Theraprutics)	STING agonist ADC*	Cancer
belantamab (2857914)	Anti-BCMA antibody	Multiple myeloma
4524101	DNA polymerase theta inhibitor*	Cancer ⁵
5733584 (HS-20089)	ADC-targeting B7-H4*	Gynecologic malignancies
4172239	DNMT1 inhibitor*	Sickle cell disease

*In-licence or other alliance relationship with third party ** Additional indications or candidates also under investigation ^ In registration 1. Phase III trial in patients with progranulin gene mutation 2. Metered dose inhaler 3. Phase III start expected in 2024 4. Approved in US and EU 5. In phase I/II study 6. Phase II study start imminent 7. Transition activities underway to enable further progression by partner 8. GSK has an exclusive global license option to co-develop and commercialise the candidate

Changes since Q3 2023

Changes on pipeline

New to Phase I

4024484 – *P. falciparum* whole cell inhibitor, malaria 3862995 – Anti-IL33 antibody, COPD 5462688 – RNA-editing oligonucleotide, Alpha-1 antitrypsin deficiency 4347859 – Interferon pathway modulator, systemic lupus erythematosus 5733584 – ADC targeting B7-H4, gynecologic malignancies

New to Phase II

3943104 – Recombinant protein, adjuvanted, Therapeutic HSV 5637608 – HBV-targeted siRNA sequential combination, chronic HBV infection 4077164 – Bivalent GMMA, Invasive non-typhoidal salmonella** 4524184 – Integrase inhibitor, HIV

New to Phase III

Low carbon version of MDI, Ventolin – Beta 2 adrenergic receptor agonist, asthma


Removed from Phase I



4429016 – Bioconjugated recombinant protein, adjuvanted, *K. pneumoniae* 4182137 (VIR7832) – Anti-spike protein antibody, COVID-19

Removed from Phase II

VIR2482 – Neutralising monoclonal antibody, influenza




Achieved pipeline catalysts

Regulatory decisions

<i>Nucala</i> – severe asthma	CN
Jemperli ¹ – RUBY, dMMR/MSI-H 1L endometrial cancer	EU
Omjjara: MOMENTUM, myelofibrosis	EU

Regulatory submission acceptances



EU, JP

Other events



Blenrep – DREAMM-7, 2L+ MM – Positive headline phase III data Jemperli¹ – RUBY (Part 2), 1L EC – Positive phase III data readout

► Glossary

ADC	Antibody drug conjugate
AE	Adverse event
AESI	Adverse event of special interest
AUC	Area under curve
BCMA	B-cell maturation antigen
BICR	Blinded Independent Central Review
BRCA	Breast cancer
CAE	Corneal adverse events
CBR	Clinical benefit rate
cCR	Complete clinical response
CKD	Chronic kidney disease
CfB	Change from baseline
CMV	Cytomegalovirus
CN	China
COPD	Chronic obstructive pulmonary disease
СР	Cholestatic pruritus
CRR	Complete response rate
CRSwNP	Chronic rhinosinusitis with nasal polyps
cUTI	Complicated urinary tract infection
CV	Cardiovascular
DDI	Drug-drug interaction
DFS	Disease-freee survival
DL	Dose level
DLT	Dose-limiting toxicity
dMMR	Deficient mismatch repair
DoR	Duration of response
DPNP	Diabetic peripheral neuropathic pain
EASI	Eczema Area and Severity Index

EGPA	Eosinophilic granulomatosis with polyangiitis
FVC	Forced vital capacity
GC	Urogenital gonorrhea
GMMA	Generalised Modules for Membrane Antigens
GSI	Gamma secretase inhibitor
HA	Healthy adults
HBV	Hepatitis B virus
HES	Hypereosinophilic syndrome
Hgb	Hemoglobin
hSBA	Human serum bactericidal assay
HZ	Herpes zoster
IC	Immunocompromised
ICR	Independent central review
iNTS	Invasive non-typhoidal salmonella
ITT	Intention-to-treat
JP	Japan
LLOQ	Lower limit of quantitation
LRTS	Lower respiratory tract symptoms
MAD	Multiple ascending dose
MAE	Medical attended events
MDI	Metered dose inhaler
MAPS	Mulitple Antigen Presenting System
MM	Multiple myeloma
MMR	Measles, mumps and rubella
MMRV	Measles, mumps, rubella and varicella
MRD	Multiple rising dose
MSI-H	Microsatellite instability high
NASH	Nonalcoholic steatohepatitis
NRS	Numeric Rating Scale

NSCLC	Non-small cell lung cancer
OMV	Outer membrane vesicle
ORR	Overall response rate
OS	Overall surival
PBC	Primary biliry cholangitis
PFS	Progression-free survival
PFS2	Time to second disease progression or death
РК	Pharmacokinetic
PMF	Primary myelofibrosis
Post-PV/ET MF	Post-essential thrombocythemia myelofibrosis
RCC	Refractory chronic cough
RL	Repeat dose level
RRMM	Relapsed/refractory multiple myeloma
RSV	Respiratory syncytial virus
SAD	Single ascending dose
SAE	Serious adverse event
siRNA	Small interfering RNA
SoC	Standard of care
SSc-ILD	Systemic sclerosis associated interstitial lung disease
ТОС	Test of cure
TTBR	Time to best response
TTD	Time to treatment discontinuation
ТТР	Time to tumour progression
TTR	Time to treatment response
UTI	Urinary tract infection
uUTI	Uncomplicated urinary tract infection
VGPR	Very good partial remission
VSP	Vital sign parameters
YoA	Years of age

Assumptions and basis of preparation related to 2024 guidance, 2021-26 and 2031 outlooks

In outlining the guidance for 2024 and outlooks for the period 2021-2026 and for 2031, the Group has made certain assumptions about the macro-economic environment, the healthcare sector (including regarding existing and possible additional governmental legislative and regulatory reform), the different markets and competitive landscape in which the Group operates and the delivery of revenues and financial benefits from its current portfolio, its development pipeline and restructuring programmes.

2024 Guidance

These planning assumptions as well as operating profit and earnings per share guidance and dividend expectations assume no material interruptions to supply of the Group's products, no material mergers, acquisitions or disposals, no material litigation or investigation costs for the Company (save for those that are already recognised or for which provisions have been made) and no change in the Group's shareholdings in ViiV Healthcare. The assumptions also assume no material changes in the healthcare environment or unexpected significant changes in pricing as a result of government or competitor action. The 2024 guidance factors in all divestments and product exits announced to date.

2021-26 and 2031 outlooks

The assumptions for GSK's updated revenue, operating profit, operating margin and cash flow outlooks, 2031 revenue outlook and margin expectations through dolutegravir loss of exclusivity assume the delivery of revenues and financial benefits from its current and development pipeline portfolio of drugs and vaccines (which have been assessed for this purpose on a risk-adjusted basis, as described further below); regulatory approvals of the pipeline portfolio of drugs and vaccines that underlie these expectations (which have also been assessed for this purpose on a risk-adjusted basis, as described further below); no material interruptions to supply of the Group's products; successful delivery of the ongoing and planned integration and restructuring plans; no material mergers, acquisitions or disposals or other material business development transactions; no material litigation or investigation costs for the company (save for those that are already recognised or for which provisions have been made); no share repurchases by the company; and no change in the shareholdings in ViiV Healthcare. GSK assumes no premature loss of exclusivity for key products over the period.

The assumptions for GSK's updated revenue, operating profit, operating margin and cash flow outlooks, 2031 revenue outlook and margin expectations through dolutegravir loss of exclusivity also factor in all divestments and product exits announced to date as well as material costs for investment in new product launches and R&D. Risk-adjusted sales includes sales for potential planned launches which are risk adjusted based on the latest internal estimate of the probability of technical and regulatory success for each asset in development. Potential future sales contribution from *Blenrep* have not been included.

Notwithstanding these outlooks and expectations, there is still uncertainty as to whether our assumptions, outlooks and expectations will be achieved, including based on the other assumptions outlined above.

All outlooks statements are given on a constant currency basis and use 2023 average exchange rates as a base (£1/\$1.24, £1/€1.15, £1/Yen 175). 2021-2026 outlook refers to the 5 years to 2026 with 2021 as the base year.

Use of GSK conference call, webcast and presentation slides

The GSK plc webcast, conference call and presentation slides (together the 'GSK materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the GSK materials in any way. You may not edit, alter, adapt or add to the GSK materials in any way, nor combine the GSK materials with any other material. You may not download or use the GSK materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the GSK materials. You may not use the GSK materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. GSK plc, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. Telephone +44 20 8047 5000, www.gsk.com

GSK



